Company intelligence / Profile preview

ElsaLys Biotech

Lyon, Auvergne-Rhone-Alpes, Franceorpha.net ↗

Ownership: Private
Employees: ~8
Development stage: Phase 3

Overview

Inolimomab is being administered in France before marketing authorization in Europe for acute cortico-resistant or corticosteroid-dependent graft-versus-host disease. Around 30 patients in France were treated with inolimomab during its first year under compassionate use authorization (cATU) despite the pandemic[3].

Therapeutic areas: HematologyImmunology
Modalities: Therapeutic antibodiesMonoclonal antibodiesImmunotherapy
Industry: Biotech

Drug pipeline

3 assets

inolimomab

Phase 3

Indications: Steroid-refractory acute Graft-versus-Host Disease

2 more assets in the full pipeline.

Request access →

Partnerships

EFSCurie InstituteTumor Institute of TurinSATT-Sud Est

Beyond the preview

Go deeper on ElsaLys Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ElsaLys Biotech.

Explore the full profile